Targeting p21 ‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Advanced Science · 2026
DOI: 10.1002/advs.76384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Na Ta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Portal Vein, Kupffer Cells. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Educational funding of Liaoning Province, Liaoning Provincial Science and Technology Plan Projects.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) are associated with a significantly poor prognosis and limited treatment options. Single‐cell RNA sequencing (scRNA‐seq) has revealed senescent Kupffer cells (sKCs), which are characterized by high levels of p21 expression and enriched in the tumor microenvironment (TME) of HCC‐PVTT. These sKCs exhibit a pronounced senescence‐associated secretory phenotype (SASP), promoting the proliferation and invasion of tumors and crosstalk with cancer‐associated fibroblasts. To target sKCs, a biomimetic nanodelivery system termed SKEV@AAV has been developed. This system comprises adeno‐associated virus (AAV) vectors carrying p21 ‐specific shRNA, encapsulated within sKCs‐derived exosomes (SKEV). SKEV@AAV effectively downregulated p21 , suppressed SASP signaling, and disrupted pro‐tumor interactions between sKCs and cancer‐associated fibroblasts. In an orthotopic PVTT model, SKEV@AAV showed single‐agent antitumor activity and attenuated SASP‐associated inflammatory remodeling. Furthermore, the combination efficacy with anti‐PD‐1 was evaluated in a murine splenic liver‐metastasis model, where SKEV@AAV reduced tumor burden, enhanced CD8 + T‐cell infiltration, decreased regulatory T cells, and promoted memory T‐cell differentiation. Our findings reveal a pivotal role of sKCs in mediating immune suppression in HCC‐PVTT and provide a nanotherapeutic strategy that reverses sKCs' senescence, reprograms the TME, and ultimately enhances antitumor immune activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, P. R. China.
- Department of Neurology, The Second Affiliated Hospital of Dalian Medical University, Dalian, P. R. China.
- Department of Pharmacy, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
- Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
- The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, Liaoning, P. R. China.
- School of Medicine, Southern University of Science and Technology, Shenzhen, P. R. China.
ORCID-Profile: Aoran Liu, Tingsong Chen, Qiuhua Luo, Tao Han
Förderung
- National Natural Science Foundation of China
- Educational funding of Liaoning Province
- Liaoning Provincial Science and Technology Plan Projects
- Shenyang Young and Middle-aged Science and Technology Innovation Talent Support Program
- Shenyang Science and Technology Plan Projects
- New Quality Clinical Specialty Program of High-end Medical Disciplinary Construction in Shanghai Pudong New Area
- Key Discipline Program of the Shanghai Pudong New Area Health Commission
- Liaoning Provincial Department of Science and Technology Joint Project
Zitieren
APA
Ta, N., Wang, S., Zhang, B., Liu, N., Han, Y., Liu, A., Xu, Y., Chen, T., Zhang, Y., Luo, Q., & Han, T. (2026). Targeting p21 ‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Advanced Science. https://doi.org/10.1002/advs.76384
Vancouver
Ta N, Wang S, Zhang B, Liu N, Han Y, Liu A, et al. Targeting p21 ‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Advanced Science. 2026. doi:10.1002/advs.76384
BibTeX
@article{Ta2026,
author = {Ta, Na and Wang, Shuyi and Zhang, Boyan and Liu, Ning and Han, Yingchen and Liu, Aoran and Xu, Ying and Chen, Tingsong and Zhang, Ye and Luo, Qiuhua and Han, Tao},
title = {Targeting p21 ‐High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76384}
}
EUVIMED